Nice sentiment if you were waiting for an 11th hour call to go to senior prom or homecoming dance but not much of an investment strategy.
1) If they move from NASDAQ to the "pink sheets" you're still a shareholder in a company whose shares have less liquidity and probably no institutional support. It will have a negative impact on the value of your shares.
3) In all likelihood your shares would be purchased by the buyer. The hypothetical buyer wouldn't want minority shareholders to contend with. The securities laws will offer you some protection as a small shareholder.
4) The company would have to qualify for listing on the NASDAQ again. You would still own your shares and they would be marketable but less liquid as they would continue to be if the company was traded on the pink sheets.
5) Not sure what you're asking here. The quality of the products is of little value when the quality of management is so poor and the treatment of minority shareholders is so deplorable.
And specifically why am i going to be sorry for myself? I'm long MDXG with most of stock at $1 and covered my OSIR shorts below $8. You sound an awful lot like the recently departed Ozark who would make nonsensical assertions.
How is one an informed long when your source of financial information for determining sales is a small part of total sales? I don't think you can extrapolate VA sales and create an accurate snapshot of the top line. The positive qualitative information for this tends to be all subjective, i.e. product quality. The negative qualitative information is all objective, i.e. criminal investigation, restated financials, 3 ceos, auditing firm resignations. Again, how are you an informed long?
You have put your finger on the problem whether intentionally or not. This company looks to be a private company in drag operated for the benefit of its majority shareholder. Unfortunately, it's difficult to attract and retain top management without the ability to reward them with a stock that has potential unless you are in a position to pay large cash compensation packages which this company isn't. The lack of transparency, what appears to be no urgency as regards production of financial statements, last year's large dividend (who benefited primarily?) and a history of little shareholder communications beyond what is SEC required all help to make this a poorly institutionally sponsored stock. Makes you wonder if it's the majority shareholder's intention to take it private on the cheap.
I am out of here.
For the fiscal years ended June 30 2015 and 2014 MESO lost $81M and $119M on sales of $37M and $43M, respectively. For the nine months ended March 31, 2016 and 2015, MESO lost $52M and $66M on sales of $16M for both periods. MESO has a fair amount of cash on hand but its cash burn is high and will find it difficult to raise equity in this biotech environment. All numbers are in AUS $s. How exactly does is work well for both by combining them and how are they on the right track? Of course we can't compare with Osiris' financial statements.
I understand the point of having a public company is to create shareholder value and it doesn't appear that being a putative scientific leader has generated much shareholder value. It looks like they've monetized their intellectual property in the past by selling it to generate working capital to fund becoming an operating company. Are operations profitable enough to avoid selling ip again?
That's quite an amount of nonsensical statements demonstrating your lack of knowledge of corporate governance and the relationship between independent accounting firms and their publicly traded clients. Do you just make this stuff up as you go or have you actually attempted to research a topic that you opine upon?
What's going to be the catalyst that propels OSIR? Other than your unwarranted enthusiasm for the company, you've yet to cite any objective information that would make OSIR worth investing in.
At least you're consistently wrong but seldom in doubt. You just parroted what your OSIR's incompetent and opaque management has been saying for months. Why do you believe them?
I've seen plenty of blood in the street, i.e. Wacholvia, AIG. Valeant, etc, Some times it's because the body is bleeding out and sometimes because it's only wounded. There's not enough objective information to determine a prognosis at this point. Waiting might cost you a few dollars on the top side but if it's the blockbuster you think it is, that would be small potatoes. I think it will be $4 before it's $10.
Please consult with Mr Webster and familiarize yourself with the definition of these words. You're quite ignorant financially and grammatically
Really! Osiris is using " Investor Relations and/or Key Management executive assistants" to monitor stock boards? I would hope "Key Management executive assistants" and anyone else working for Osiris would be trying to manufacture and sell product, create new product, get financial statements out the door and increase shareholder value. if you have "Key Management executive assistants" with time to putz around on message boards, that might explain prior operating results.
Can this data be extrapolated to estimate top line revenue for the 1rst and 2nd quarters?
I understand there are ways to protect intellectual property called patents and copyrights. If you have any influence with Oisris' executives of the week, you might want to familiarize them with these legal concepts if in fact they actually have something that can be patented or copyrighted. I understand Mimedex has availed itself of the patent process and protects its intellectual property vigorously.
Just noticed your supposition regarding insider trading involving the CEO of another company and an analyst. I hope you are not offended but that is nonsensical.
Ozark580's statements intrigued me. Why would combining with MESO whose revenues are either declining or stagnant be to Osiris's benefit? MESO also comes with currency risks. MESOs' stock price looks to be headed to drill bit size.